HEALTH

Bolar Settles Warner-Lambert Suit: Bolar Pharmaceutical Co., the maker of generic drugs embroiled in a fraud scandal, has settled a lawsuit with Warner-Lambert Co. for $7 million. Warner-Lambert filed the suit against Bolar and its former president, Robert Shulman, in a dispute over Bolar’s generic versions of three drugs made by Warner-Lambert’s Parke-Davis division. Warner-Lambert alleged that Bolar submitted false data in seeking approval to make a generic version of Dilantin, a leading drug for treating epileptic seizures. Warner-Lambert did not elaborate on the other drugs involved. Bolar, based in Copiague, N.Y., pleaded guilty last year to federal criminal charges of selling adulterated and mislabeled generic drugs.